December 2018 PMID 30566006

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, Itamar Raz, Bryan Goldman, Thomas Idorn, Bernt Johan von Scholten, Neil R Poulter

Download social card

Mentions

Peak: 2 in Jan 2019

across 4 sources since Oct 2018

Extended reach

19,587

potential audience

Total likes

Video views

416

Mentions per month

Oct 2018 – Oct 2025

Where it's discussed

X / Twitter4 posts
YouTube2 videos
Facebook2 posts
News2 articles

AI synopsis

What people are saying

The analyzed discussions reveal a mostly supportive tone with mentions of liraglutide reducing cardiovascular risks in diabetic patients with chronic kidney disease, especially in cases with impaired kidney function; words like 'effectively' and 'potential' suggest a focus on significant clinical implications, while curiosity about different patient responses reflects high interest and engagement.

AgreementModerate agreement

Most discussions seem to acknowledge the study’s findings, with some posts explicitly supporting the benefits of liraglutide for cardiovascular risk reduction in specific patient groups.

InterestHigh interest

Multiple posts demonstrate strong curiosity and positive engagement with the research, highlighting relevance to diabetes and kidney disease treatments.

EngagementModerate engagement

Comments often reference detailed aspects of the trial or patient implications, indicating moderate to deep engagement rather than superficial reactions.

ImpactModerate impact

The discussions recognize the potential clinical importance of the study, though some posts are more reflective than transformative in tone, indicating a moderate perceived impact.

Abstract in brief

The study found that liraglutide reduces the risk of major cardiovascular events, especially in patients with type 2 diabetes and chronic kidney disease who have an eGFR of 60 mL/min/1.73 m² or lower, showing a greater benefit in this group.
Liraglutide's benefits on cardiovascular outcomes were less clear in patients with higher kidney function (eGFR above 60), and the effectiveness varied across different levels of kidney function, with some statistical interaction.
Overall, liraglutide not only helps reduce cardiovascular risks but also shows more significant effects in patients with impaired kidney function, indicating its potential as a treatment option for those with both diabetes and kidney disease.]

Read the full abstract

All mentions

Liraglutide's Impact on Cardiovascular Events in Diabetic Kidney Disease

This video reviews recent findings on liraglutide, which reduces major cardiovascular events, especially in patients with type 2 diabetes and chronic kidney disease with eGFR of 60 or lower. The benefits are less clear…

CardioLearning · Oct 9, 2018 396 views

GLP-1 and Liraglutide: Cardiovascular Benefits and Muscle Loss Risks

No fluff just science distilled from 100 recent studies and metaanalyses. Liraglutide reduces cardiovascular risk, especially in patients with kidney disease, but potential muscle loss concerns remain. Insights based on…

Longevity Lift Off · Oct 24, 2025 20 views

Edward Enterprises

@EdwardEnterpri3 · X

May 4, 2020 · 628 followers View post →

jordi mesa

@jmm253 · X

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. https://t.co/ypyKG7YO9F

Feb 16, 2019 · 1 like · 223 followers View post →

Cristobal Morales

@CristobMorales · X

RT @vic_pallares: Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidn…

Jan 10, 2019 · 28 shares · 17,148 followers View post →

FUNDAPROCECA

@FUNDAPROCECA · X